Detection of B-type natriuretic peptide by establishing a low-cost and replicable fluorescence resonance energy transfer platform

Tu, Aiping; Shang, Jinsai; Di, Li; Liu, Laicheng; Zhang, Gan; Yin, Yibing; Zhang, Pu

doi:10.1007/s00604-020-04247-1

Cited by 16 publications

(9 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nanomaterial-based fluorescence biosensors for high sensitivity and shortened analysis time of fluorescence nanosensor assays, such as Fe 2 O 3 @SiO 2 @Eu-MOF@Tb-MOF core/multishell, zirconium metal–organic framework with CdTeNPs, graphitic carbon nitride quantum dots, GO, Ti NCs, CdSe/ZnS QDs, etc., are used for the detection of important AMI biomarkers, including CK-MB, CTn, BNP, and Mb. A graphene oxide-based FRET sensing platform for the detection of B-type natriuretic peptide (BNP) achieved a limit of detection of 45 fg/mL (ref ).…”

Section: Discussionmentioning

confidence: 99%

“…192 Zhang et al developed a cost-effective FRET sensing platform for the detection of B-type natriuretic peptide (BNP) using graphene oxide (GO). 193 In this assay FRET occurs between the nano platform, GO as energy acceptor, and the FAM-aptamer acts as an energy donor. This fluorescent sensor was successfully used to detect BNP in 45 blood samples in the range of 0.074−0.56 pg/mL with a limit of detection as low as 45 fg/mL (3σ).…”

Section: Optical Signaling Readout-based Nanobiosensorsmentioning

confidence: 99%

“…Another report also uses carbon dots and palladium–iridium nanocubes-based ratiometric fluorescent immunoassay for selective detection of cTnI with 0.31 pg/mL (LOD) sensitivity . Zhang et al developed a cost-effective FRET sensing platform for the detection of B-type natriuretic peptide (BNP) using graphene oxide (GO) . In this assay FRET occurs between the nano platform, GO as energy acceptor, and the FAM-aptamer acts as an energy donor.…”

Section: Optical Signaling Readout-based Nanobiosensorsmentioning

confidence: 99%

See 2 more Smart Citations

Optical Nanobiosensor-Based Point-of-Care Testing for Cardiovascular Disease Biomarkers

Vairaperumal,

Huang,

Liu

2023

ACS Appl. Bio Mater.

View full text Add to dashboard Cite

Cardiovascular disease is a global health threat, and detecting cardiac biomarkers is essential for early-stage diagnosis and personalized treatment. Traditional approaches have limitations, but optical nanobiosensors offer rapid, highly selective, and sensitive detection. Optical nanobiosensors generate biosignals that transfer light signals while analytes bind with the bioreceptors. Optical nanobiosensors have advantages such as ease of monitoring, low cost, a wide detection range, and high sensitivity without any interference. An optical nanobiosensor platform is a promising approach for point-of-care cardiac biomarker detection with a low detection limit. This review mainly focuses on the detection of cardiovascular disease biomarkers based on various optical nanobiosensor approaches that have been reported during the last five years, and we have categorized them based on optical signal readouts. A detailed discussion of the classification of cardiovascular disease biomarkers, design strategies of optical biosensors, types of optically active nanomaterials, types of bioreceptors, functionalization techniques, various assay types, and sensing mechanisms is presented. Then, we summarize the optical signaling readout-based various nanobiosensors systems for the detection of cardiovascular disease biomarkers. Finally, we summarize and conclude with the recent development of point-of-care testing (PoCT) for cardiovascular disease biomarkers used in various optical readout techniques.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Optical Signaling Readout-based Nanobiosensorsmentioning

confidence: 99%

Section: Optical Signaling Readout-based Nanobiosensorsmentioning

confidence: 99%

See 1 more Smart Citation

Optical Nanobiosensor-Based Point-of-Care Testing for Cardiovascular Disease Biomarkers

Vairaperumal,

Huang,

Liu

2023

ACS Appl. Bio Mater.

View full text Add to dashboard Cite

show abstract

“…The LOD of this biosensor was 10 pg/ml and the linear detection range was from 100 to 50000 pg/ml ( Chen et al, 2022 ). Moreover, aptamer technology has also been implemented in the detection of other cardiac biomarkers, such as B-type natriuretic peptide ( Tu et al, 2020 ), C-reactive protein ( Wang et al, 2017 ), and myoglobin ( Nia and Azadbakht, 2018 ).…”

Section: Aptamer-based Cardiac Disease Diagnosismentioning

confidence: 99%

Aptamer-based applications for cardiovascular disease

Chen

Xie

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Cardiovascular disease (especially atherosclerosis) is a major cause of death worldwide, and novel diagnostic tools and treatments for this disease are urgently needed. Aptamers are single-stranded oligonucleotides that specifically recognize and bind to the targets by forming unique structures in vivo, enabling them to rival antibodies in cardiac applications. Chemically synthesized aptamers can be readily modified in a site-specific way, so they have been engineered in the diagnosis of cardiac diseases and anti-thrombosis therapeutics. Von Willebrand Factor plays a unique role in the formation of thrombus, and as an aptamer targeting molecule, has shown initial success in antithrombotic treatment. A combination of von Willebrand Factor and nucleic acid aptamers can effectively inhibit the progression of blood clots, presenting a positive diagnosis and therapeutic effect, as well as laying a novel theory and strategy to improve biocompatibility paclitaxel drug balloon or implanted stent in the future. This review summarizes aptamer-based applications in cardiovascular disease, including biomarker discovery and future management strategy. Although relevant applications are relatively new, the significant advancements achieved have demonstrated that aptamers can be promising agents to realize the integration of diagnosis and therapy in cardiac research.

show abstract

“…[ 6 ] The blood BNP concentration for healthy individuals is extremely low at around 20 pg mL −1 (6 × 10 −12 m ), and it raises to around 2 ng mL −1 (600 × 10 −12 m ) for patients with severe congestive HF. [ 7 ] Various analytical methods have been employed for the detection of low‐abundant BNP in blood samples, which include electrochemical and electrochemiluminescent detections, [ 8 ] surface plasmon resonance (SPR), [ 9 ] mass spectrometry, [ 10 ] fluorescence resonance energy transfer platform, [ 11 ] impedimetrical detection, [ 12 ] field‐effect‐transistor (FET) biosensor, [ 13 ] and digital volumetric bar‐chart chip. [ 14 ] However, due to the pictogram‐level of BNP content in the complex biological samples and its short half‐life of mere 22 min in vivo, most of the current detection methods do not fulfill the requirements of accuracy and high speed.…”

Section: Introductionmentioning

confidence: 99%

Solid‐Phase Screening and Synthesis of Molecularly Imprinted Nanoparticles for Selective Recognition and Detection of Brain Natriuretic Peptide

Zhang

Yuan

et al. 2023

Adv Healthcare Materials

View full text Add to dashboard Cite

A new recognition method is explored for the rapid detection of B-type natriuretic peptide (BNP) based on the rational design and solid-phase synthesis of molecularly imprinted nanoparticles (nanoMIP) encapsulated with carbon dots. The nanosized magnetic template is first prepared by attaching the epitope of BNP on amino-functionalized magnetic carriers. High-dilution polymerization of monomers in the presence of magnetic template generates lightly crosslinked imprinted nanoparticles. To obtain the optimal MIP formulation, a new combinatorial screening approach is developed by a competitive fluorescence assay using the magnetic template. The resultant nanoMIP exhibits high affinity and selectivity toward BNP with an equilibrium dissociation constant (K D ) of ≈10 −11 m. The proposed assay allows fast BNP detection within ≈7 min with a linear range of its concentration from 0.25 to 5000 pg mL −1 and a limit of detection of 0.208 pg mL −1 (S/N = 3). To demonstrate its practicability in clinical diagnosis, unknown real serum samples from 160 individuals are analyzed and the relative standard deviation is less than 4.43%. Compared with the routine electrochemiluminescence detection method that is widely used in hospital, the relative error is less than 4.98% and the correlation coefficient is 0.994.

show abstract

Detection of B-type natriuretic peptide by establishing a low-cost and replicable fluorescence resonance energy transfer platform

Cited by 16 publications

References 32 publications

Optical Nanobiosensor-Based Point-of-Care Testing for Cardiovascular Disease Biomarkers

Optical Nanobiosensor-Based Point-of-Care Testing for Cardiovascular Disease Biomarkers

Aptamer-based applications for cardiovascular disease

Solid‐Phase Screening and Synthesis of Molecularly Imprinted Nanoparticles for Selective Recognition and Detection of Brain Natriuretic Peptide

Contact Info

Product

Resources

About